What is Zacks Research's Forecast for IOVA FY2026 Earnings?

Key Points

• Zacks Research raised its FY2026 EPS forecast for Iovance Biotherapeutics to a loss of $0.55 per share from a projected loss of $0.56, though this remains below the consensus estimate of a $0.46 loss.
• Analysts have a generally positive view of IOVA, with nine Buy ratings, two Holds and one Sell; the stock has a Moderate Buy consensus rating and a $12.40 average price target.
• Iovance’s latest quarterly results beat expectations, with revenue of $99.31 million and an EPS loss of $0.11, while revenue increased 65.7% year over year. Despite improving forecasts and higher revenue guidance, analysts expect the company to remain unprofitable through 2028.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at Zacks Research boosted their FY2026 EPS estimates for Iovance Biotherapeutics in a report released on Wednesday, September 30th. Zacks Research analyst Team now expects that the biotechnology company will earn ($0.55) per share for the year, up from their prior forecast of ($0.56). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($0.46) per share. Zacks Research also issued estimates for Iovance Biotherapeutics' Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.39) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.01) EPS, Q3 2028 earnings at $0.00 EPS and FY2028 earnings at ($0.03) EPS.

IOVA has been the topic of several other research reports. Citizens Jmp boosted their target price on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. The Goldman Sachs Group began coverage on Iovance Biotherapeutics in a research report on Thursday, September 24th. They set a "buy" rating and a $15.00 price target for the company. Mizuho upped their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. UBS Group upped their price objective on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the stock a "neutral" rating in a research report on Thursday, August 20th. Finally, TD Cowen boosted their target price on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday, August 24th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $12.40.

Iovance Biotherapeutics Stock Performance

Shares of IOVA opened at $14.23 on Friday. The company has a 50 day moving average price of $8.16 and a 200-day moving average price of $5.42. Iovance Biotherapeutics has a fifty-two week low of $1.76 and a fifty-two week high of $15.30. The stock has a market capitalization of $6.45 billion, a PE ratio of -19.49 and a beta of 0.75.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The business had revenue of $99.31 million for the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The company's quarterly revenue was up 65.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share.

Hedge Funds Weigh In On Iovance Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC purchased a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth approximately $6,406,000. Hennion & Walsh Asset Management Inc. lifted its position in Iovance Biotherapeutics by 100.0% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 818,913 shares of the biotechnology company's stock valued at $3,407,000 after buying an additional 409,449 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Iovance Biotherapeutics in the second quarter worth about $2,726,000. Palo Alto Investors LP acquired a new stake in Iovance Biotherapeutics during the 2nd quarter valued at $22,032,229. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Iovance Biotherapeutics during the 2nd quarter worth approximately $449,000. Institutional investors and hedge funds own 77.03% of the company's stock.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised its 2026 revenue outlook to $410 million-$420 million, citing strong demand for its marketed therapies. The improved guidance was the primary catalyst behind the recent rally and signals better-than-expected commercial momentum. IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
• Positive Sentiment: Analysts are becoming more optimistic about IOVA’s earnings trajectory. Zacks Research raised multiple quarterly forecasts, lifted its FY2026 estimate to a loss of $0.55 per share from $0.56, and improved its FY2027 and FY2028 forecasts to losses of $0.39 and $0.03, respectively. HC Wainwright also raised estimates, maintains a Buy rating, and has a $20 price target. Wells Fargo raised its target to $18 and assigned an Overweight rating. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
• Neutral Sentiment: Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer. His global drug-development experience in T-cell therapies could support pipeline execution, although the appointment is unlikely to materially change near-term financial results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
• Negative Sentiment: Despite improving forecasts, IOVA remains unprofitable, with analysts still projecting losses through 2028. After the stock’s rapid advance and move near its 12-month high, investors may be taking profits, while the elevated expectations leave the shares vulnerable if revenue growth or commercialization momentum slows.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company's platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.